Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYuyang GaoMZMingzhi Zhang

Discussion

Loading...

Member takes

Overview

Engineering bispecific CAR T-cells targeting tumor antigens improves antitumour activity in B cell lymphoma, suggesting new treatment avenues.

Key Points

  • The aim is to develop bispecific CAR T-cells targeting CD79b and CD19 for enhanced efficacy against B cell lymphomas.
  • Developed anti-CD79b and anti-CD19 monoclonal antibodies using hybridoma technology and single B-cell cloning.
  • Engineered CAR constructs including CD79b-CAR, CD19-CAR, and bispecific versions.
  • Conducted cytotoxicity assays and in vivo tests using B-cell lymphoma models.
  • Utilized lentiviral transduction into primary human T cells for functional characterization.
  • CD79b and CD19 showed high expression in B-cell lymphoma cell lines.
  • All engineered CAR-T cell lines displayed potent anti-tumor activity, eliminating malignant B-cells.
  • In vivo studies indicated significant antitumour effects in a B-cell lymphoma mouse model.
  • CD79b/CD19 dual-targeting CAR-T cells outperformed single-target CAR-T cells in heterogeneous lymphoma cases.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2a5https://doi.org/10.1182/blood-2025-5877
View Full Paper
Ask AI
Bookmark
Share